NeoThetis: Prostate
Prostate cancer arises from the cells in the prostate gland, and it is the 2nd most common cancer in men. Prostate cancer manifests from the accumulation of mutations that cause the healthy cells of the prostate to transform into malignant cells and divide uncontrollably. The cancer cells will then form a tumour mass that will ultimately spread to nearby organs in a process known as metastasis.
This panel identifies the genetic mutations in 35 genes in the circulating tumour DNA that is released from prostate cancers. Screening for the mutations responsible for cancer progression enables the identification of FDA/EMA-approved therapies tailored to each patient with prostate cancer.
Microsatellite instability (MSI) immunotherapy biomarker has also been detected in patients with prostate cancer, and it can be used as an immunotherapy biomarker for men with advanced prostate cancer. The FDA-approved drug pembrolizumab can be used as an immunotherapy option for MSI-high patients.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?


Certified laboratories

